Welo(@Hello_Welo) 's Twitter Profile Photo



Prostate cancer that's detected early — when it's still confined to the prostate gland — has the best chance for successful treatment. GENTS our time is now, let's get checked out. ❤️♂️

#MensHealthMonth 
#ProstateCancer
Prostate cancer that's detected early — when it's still confined to the prostate gland — has the best chance for successful treatment. GENTS our time is now, let's get checked out. ❤️♂️
account_circle
Up Heath & Wellness(@UPhealthandwell) 's Twitter Profile Photo

Tomorrow on Real Patients: Metastatic Hormone — Sensitive Prostate Cancer (mHSPC) with Dr. Sebastien Hotte Tune in here@11:00am EST 6-21, for full episode. awareness

account_circle
Wissam Abou Chedid(@Wis_Abou_Chedid) 's Twitter Profile Photo

It was a pleasure to present our experience with post at Our poster was awarded the first prize in the Prostate Cancer session, a testament to Royal Surrey that continues to lead the way in care Prostate Cancer UK The Prostate Project

It was a pleasure to present our experience with #Self_TWOC post #RARP at #BAUS23 Our poster was awarded the first prize in the Prostate Cancer session, a testament to #teamawesome @RoyalSurrey that continues to lead the way in #prostatecancer care @ProstateUK @_ProstateProjec
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Metastatic prostate cancer costs are staggering - over $55K per person-year for employer-insured men, $43K for those on Medicare supplements.
These figures underscore the need for more cost-effective prevention, screening, and treatment.

Metastatic prostate cancer costs are staggering - over $55K per  person-year for employer-insured men, $43K for those on Medicare  supplements. 
These figures underscore the need for more cost-effective  prevention, screening, and treatment. #ProstateCancer #HealthEconomics…
account_circle
Neeraj Agarwal, MD, FASCO(@neerajaiims) 's Twitter Profile Photo

We report in The Lancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert UroToday.com PCF Science

We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science
account_circle
Neeraj Agarwal, MD, FASCO(@neerajaiims) 's Twitter Profile Photo

Breaking news👉U.S. FDA approves Talazoparib + Enzalutamide for mCRPC with HRR mutations. Weblink👉 tinyurl.com/bdhabbkt Efficacy data, HRR mutations👇Prostate Cancer Foundation OncoAlert UroToday.com Huntsman Cancer Institute Gratifying to see the success of this trial we started 6 yrs ago

Breaking news👉@US_FDA approves Talazoparib + Enzalutamide for mCRPC #prostatecancer with HRR mutations. Weblink👉 tinyurl.com/bdhabbkt Efficacy  data, HRR mutations👇@PCFnews @OncoAlert @urotoday @huntsmancancer Gratifying to see the success of this trial we started 6 yrs ago
account_circle